192 related articles for article (PubMed ID: 33731288)
1. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Ozonoff A; Lee SY; Voisine M; Parker JT; Nakanishi R; Nishimura S; Yang J; Grace Z; Tran B; Diefenbach TJ; Maehara Y; Yasui H; Irino T; Salgia R; Terashima M; Gibbs P; Ramanathan RK; Oki E; Mori M; Kulke M; Hartshorn K; Bharti A
Clin Colorectal Cancer; 2021 Jun; 20(2):e129-e138. PubMed ID: 33731288
[TBL] [Abstract][Full Text] [Related]
2. [The Efficacy of topo Ⅰ-pS10 Expression in Gastric Cancer as a Predictive Biomarker for Irinotecan Use].
Ando K; Hu Q; Fujimoto Y; Jogo T; Nakanishi R; Hisamatsu Y; Kimura Y; Oki E; Bharti A; Mori M
Gan To Kagaku Ryoho; 2021 Mar; 48(3):331-335. PubMed ID: 33790151
[TBL] [Abstract][Full Text] [Related]
3. Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Tohme YH; Srinivasiah A; Taylor-Parker J; Harrington Y; Shah AK; Oki E; Brahmandam M; Bharti AK
J Histochem Cytochem; 2018 Aug; 66(8):549-561. PubMed ID: 29587004
[TBL] [Abstract][Full Text] [Related]
4. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Matsuoka H; Ando K; Swayze EJ; Unan EC; Mathew J; Hu Q; Tsuda Y; Nakashima Y; Saeki H; Oki E; Bharti AK; Mori M
PLoS One; 2020; 15(8):e0228002. PubMed ID: 32764831
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK
Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
[TBL] [Abstract][Full Text] [Related]
7. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Xu JM; Zhu BD; Mangia A; Simone G; Montemurro S; Giuliani F; Maiello E; Colucci G; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):312-5. PubMed ID: 15996331
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
14. CPT-11 in gastrointestinal cancer.
Bleiberg H
Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Nygård SB; Christensen IJ; Nielsen SL; Nielsen HJ; Brünner N; Spindler KL
Scand J Gastroenterol; 2014 Jan; 49(1):84-91. PubMed ID: 24256029
[TBL] [Abstract][Full Text] [Related]
16. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
17. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
Ishida H; Shirakawa K; Ohsawa T; Hayashi Y; Okada N; Nakada H; Yokoyama M
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1295-9. PubMed ID: 16184927
[TBL] [Abstract][Full Text] [Related]
19. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of irinotecan efficacy.
Vallböhmer D; Iqbal S; Yang DY; Rhodes KE; Zhang W; Gordon M; Fazzone W; Schultheis AM; Sherrod AE; Danenberg KD; Lenz HJ
Int J Cancer; 2006 Nov; 119(10):2435-42. PubMed ID: 16894565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
